16 results on '"Nakanishi, Yoichi"'
Search Results
2. Breakthrough chemotherapy-induced nausea and vomiting: report of a nationwide survey by the CINV Study Group of Japan.
- Author
-
Tamura, Kazuo, Aiba, Keisuke, Saeki, Toshiaki, Nakanishi, Yoichi, Kamura, Toshiharu, Baba, Hideo, Yoshida, Kazuhiro, Yamamoto, Nobuyuki, Kitagawa, Yuko, Maehara, Yoshihiko, Shimokawa, Mototsugu, Hirata, Koichi, and Kitajima, Masaki
- Subjects
CANCER chemotherapy ,NAUSEA ,VOMITING ,METOCLOPRAMIDE ,ANTIPSYCHOTIC agents - Abstract
Background: We conducted a nationwide survey on chemotherapy-induced nausea and vomiting (CINV) in Japan and demonstrated good compliance with Japanese CINV guidelines, resulting in good control of vomiting. However, almost half the patients experienced breakthrough CINV. We analyzed the survey results in relationship to the management of patients with breakthrough CINV. Methods: This multicenter, prospective, observational study analyzed data for 1910 patients in Japan scheduled for moderately or highly emetogenic chemotherapy (MEC and HEC, respectively). Patients who developed CINV despite prophylactic use of antiemetics were administered rescue drugs. Patients who received cisplatin-based HEC (C-HEC), non-cisplatin-based HEC (N-HEC), or MEC were evaluated separately. Results: A total of 989 patients experienced CINV, of whom 412 (44%) received rescue antiemetics during the study period. The rate at which patients with breakthrough CINV were started on rescue drugs ranged from 13% to 24%. Rescue drugs were given more frequently on days 2-4 for C-HEC and MEC and on days 1-2 for N-HEC. Eighty-six percent of patients received metoclopramide or domperidone. 5-HT receptor antagonists, antipsychotics, and anti-anxiety drugs were used for 11-5% of patients. The mean duration of antiemetic use was 2.6 days. Conclusions: Fewer than half of the patients with breakthrough CINV were treated with rescue antiemetics, suggesting that CINV was mild in the remaining patients. However, CINV was sufficiently severe to prevent eating in other patients, indicating the need for new drugs with different mechanisms to control CINV. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
3. Longitudinal assessment of pain management with the pain management index in cancer outpatients receiving chemotherapy.
- Author
-
Fujii, Akiko, Yamada, Yu, Takayama, Koichi, Nakano, Takako, Kishimoto, Junji, Morita, Tatsuya, and Nakanishi, Yoichi
- Subjects
PAIN management ,CANCER chemotherapy ,OUTPATIENT medical care ,ANALGESICS ,DIAGNOSIS of mental depression ,FOLLOW-up studies (Medicine) ,LONGITUDINAL method ,QUESTIONNAIRES ,TUMORS ,PAIN measurement ,DISEASE prevalence ,BRIEF Pain Inventory - Abstract
Purpose: The adequacy of pain management for individuals with cancer who receive outpatient chemotherapy is unclear. The primary objective of this study was to assess pain prevalence and intensity in such patients. The secondary objectives included assessment of pain management with the pain management index (PMI) and exploration of predictors of inadequate pain management.Methods: Cancer patients who received outpatient chemotherapy were enrolled. Patients were required to complete questionnaires covering demographic data and including the Brief Pain Inventory and the Distress Thermometer and Impact Thermometer. The PMI score was determined twice with an interval of at least 3 weeks.Results: Of the 740 patients enrolled in the study, 524 individuals (70.8%) completed all questionnaires. Totals of 282 patients (53.8%) and 264 patients (50.4%) reported pain at baseline and follow-up, respectively, with ∼14% of patients having moderate or severe pain at each assessment. Totals of 365 patients (69.7%) at baseline and 320 patients (61.1%) at follow-up reported pain or were prescribed analgesics, with the rate of inadequate pain management for these patients being 39.7 and 51.6%, respectively. Multivariable analysis for 418 patients (79.8%) who had pain or required analgesics at baseline or follow-up (or both) revealed that the most significant predictor of inadequate pain management was depressive state.Conclusions: Pain in cancer patients receiving outpatient chemotherapy is prevalent and at risk for undertreatment. Pain management should be assessed on a regular basis and is likely to be improved by screening for depression. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
4. Phase I study of irinotecan for previously treated lung cancer patients with the UGT1A1 * 28 or * 6 polymorphism: Results of the Lung Oncology Group in Kyushu ( LOGIK1004 A).
- Author
-
Fukuda, Minoru, Shimada, Midori, Kitazaki, Takeshi, Nagashima, Seiji, Hashiguchi, Kohji, Ebi, Noriyuki, Takayama, Koichi, Nakanishi, Yoichi, Semba, Hiroshi, Harada, Taishi, Seto, Takashi, Okamoto, Isamu, Ichinose, Yukito, and Sugio, Kenji
- Subjects
ANTINEOPLASTIC agents ,CANCER chemotherapy ,CANCER patients ,CLINICAL trials ,DRUG dosage ,DRUG toxicity ,GENETIC polymorphisms ,LUNG tumors ,IRINOTECAN - Abstract
Background Various polymorphisms have been detected in the UDP-glucuronosyltransferase 1 A ( UGT1A) gene, and UGT1A1 *28 and UGT1A1 *6 have important effects on the pharmacokinetics of irinotecan and the risk of severe toxicities during irinotecan therapy. This study was conducted to determine the maximum tolerated dose ( MTD) of irinotecan chemotherapy according to the UGT1A1 genotype in previously treated lung cancer patients with the UGT1A1 *28 or UGT1A1 *6 polymorphism. Methods The eligibility criteria were as follows: lung cancer patients that had previously been treated with anticancer agents other than irinotecan, possessed the UGT1A1 *28 or UGT1A1 *6 polymorphism (group A included *28/*28, *6/*6, and *28/*6, and group B included *28 /− and *6 /−), were aged ≤75 years old, had a performance score of 0-1, and exhibited adequate bone marrow function. The patients were scheduled to receive irinotecan on days 1, 8, 15, 22, 29, and 36. Results Four patients were enrolled in this trial. Two patients were determined to be ineligible. The remaining two patients, who belonged to group B, received an initial irinotecan dose of 60 mg/m
2 , but did not complete the planned treatment because of diarrhea and leukopenia. Thus, in group B patients, 60 mg/m2 was considered to be the MTD of irinotecan. The study was terminated in group A because of poor case recruitment. Conclusions The MTD of irinotecan for previously treated lung cancer patients that are heterozygous for the UGT1A1 * 28 or UGT1A1 * 6 gene polymorphism is 60 mg/m2 . [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
5. Durable response to nivolumab in a lung adenocarcinoma patient with idiopathic pulmonary fibrosis.
- Author
-
Ide, Maako, Tanaka, Kentaro, Sunami, Shunya, Asoh, Tatsuma, Maeyama, Takashige, Tsuruta, Nobuko, Nakanishi, Yoichi, and Okamoto, Isamu
- Subjects
ADENOCARCINOMA ,CANCER treatment ,LUNG cancer treatment ,THERAPEUTIC use of monoclonal antibodies ,IDIOPATHIC pulmonary fibrosis ,CANCER chemotherapy ,COMPUTED tomography ,DIAGNOSIS - Abstract
The efficacy and safety of immune‐checkpoint inhibitors in non‐small cell lung cancer patients with idiopathic pulmonary fibrosis (IPF) remain unknown. Herein, we describe the case of a 62‐year‐old man with multiple pleural tumors and carcinomatous pleurisy. High‐resolution computed tomography indicated usual interstitial pneumonia, and a respiratory function test revealed a restrictive disorder and decreased diffusion capacity. He was diagnosed with lung adenocarcinoma and IPF. After failure of initial chemotherapy, he was treated with nivolumab and achieved a complete response without any sign of exacerbation of IPF. The response to nivolumab has persisted for > 1 year. This is the first report of a non‐small cell lung cancer patient with IPF who has been treated with immune‐checkpoint inhibitors for such a long period and achieved a sustained response. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
6. Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non-small cell lung cancer (West Japan Oncology Group 5910L): An open-label, randomized, phase 2 trial.
- Author
-
Takeda, Masayuki, Yamanaka, Takeharu, Seto, Takashi, Hayashi, Hidetoshi, Azuma, Koichi, Okada, Morihito, Sugawara, Shunichi, Daga, Haruko, Hirashima, Tomonori, Yonesaka, Kimio, Urata, Yoshiko, Murakami, Haruyasu, Saito, Haruhiro, Kubo, Akihito, Sawa, Toshiyuki, Miyahara, Eiji, Nogami, Naoyuki, Nakagawa, Kazuhiko, Nakanishi, Yoichi, and Okamoto, Isamu
- Subjects
BEVACIZUMAB ,LUNG cancer treatment ,DOCETAXEL ,DISEASE progression ,CANCER chemotherapy ,ANTINEOPLASTIC agents ,COMPARATIVE studies ,HYDROCARBONS ,LUNG cancer ,LUNG tumors ,RESEARCH methodology ,MEDICAL cooperation ,PROGNOSIS ,RESEARCH ,STATISTICAL sampling ,EVALUATION research ,RANDOMIZED controlled trials ,PROPORTIONAL hazards models ,KAPLAN-Meier estimator - Abstract
Background: Bevacizumab combined with platinum-based chemotherapy has been established as a standard treatment option in the first-line setting for advanced nonsquamous non-small cell lung cancer (NSCLC). However, there has been no evidence to support the use of bevacizumab beyond disease progression in such patients.Methods: West Japan Oncology Group 5910L was designed as a multicenter, open-label, randomized, phase 2 trial of docetaxel versus docetaxel plus bevacizumab every 3 weeks for patients with recurrent or metastatic nonsquamous NSCLC whose disease had progressed after first-line treatment with bevacizumab plus a platinum-based doublet. The primary endpoint was progression-free survival (PFS).Results: One hundred patients were randomly assigned to receive docetaxel (n = 50) or docetaxel plus bevacizumab (n = 50), and this yielded median PFS times of 3.4 and 4.4 months, respectively, with a hazard ratio (HR) of 0.71 and a stratified log-rank P value of .058, which met the predefined criterion for statistical significance (P < .2). The median overall survival also tended to be longer in the docetaxel plus bevacizumab group (13.1 months; 95% confidence interval [CI], 10.6-21.4 months) versus the docetaxel group (11.0 months; 95% CI, 7.6-16.1 months) with an HR of 0.74 (95% CI, 0.46-1.19; stratified log-rank P = .11). No unexpected or severe adverse events were recorded.Conclusions: Further evaluation of bevacizumab beyond disease progression is warranted for patients with advanced NSCLC whose disease has progressed after treatment with bevacizumab plus a platinum-based doublet. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
7. Phase II study of concurrent thoracic radiotherapy in combination with weekly paclitaxel plus carboplatin in locally advanced non-small cell lung cancer: LOGIK0401.
- Author
-
Takayama, Koichi, Inoue, Koji, Tokunaga, Shoji, Matsumoto, Takemasa, Oshima, Tsukasa, Kawasaki, Masayuki, Imanaga, Tomotoshi, Kuba, Mutsuo, Takeshita, Masafumi, Harada, Taishi, Shioyama, Yoshiyuki, and Nakanishi, Yoichi
- Subjects
CANCER chemotherapy ,CANCER radiotherapy ,CARBOPLATIN ,PACLITAXEL ,LIVER cancer ,CLINICAL trials ,VINORELBINE ,TREATMENT duration - Abstract
Objectives: Concurrent chemoradiotherapy for regionally advanced stage III non-small cell lung cancer is the standard treatment method. However, the clinical implications of consolidation chemotherapy following chemoradiation have been unclear. Therefore, we conducted a phase II study of concurrent weekly carboplatin plus paclitaxel treatment in combination with radiotherapy followed by vinorelbine monotherapy. The primary endpoint was the 1-year survival rate. Patients and methods: Chemonaive PS 0–1 patients with stage IIIA/B NSCLC were enrolled. During the concurrent chemoradiation phase, patients were treated with weekly paclitaxel 40 mg/m
2 plus carboplatin AUC 2. The primary tumor and involved nodes received 60 Gy in 2-Gy fractions over 6 weeks. During the consolidation phase, vinorelbine 25 mg/m2 on days 1 and 8 was repeated for three cycles. Results: A total of 40 eligible patients (72.5 % male; median age, 63 years; range 29–74 years) were analyzed for efficacy. Squamous cell carcinoma was the most common histology (47.5 %), and more patients had clinical stage IIIB (55 %) cancer. The average radiation dose was 56.5 Gy, and the average number of carboplatin plus paclitaxel cycles was 4.93. Seventeen patients proceeded to the consolidation chemotherapy phase, and 14 completed three cycles of vinorelbine monotherapy. The objective response rate was 75.0 %, including 1 patient who achieved a complete response. Progression-free survival and overall survival (OS) were 46 weeks [95 % confidence interval (CI) 31–64 weeks] and 110 weeks (95 % CI 90–184 weeks), respectively. The OS rate at 1 and 2 years was 85.0 % (95 % CI 69.6–93.0 %) and 53.9 % (95 % CI 37.1–68.0 %), respectively. Conclusion: Concurrent chemoradiation with weekly carboplatin and paclitaxel followed by vinorelbine consolidation is effective for stage III non-small cell lung cancer and shows a generally mild toxicity profile. [ABSTRACT FROM AUTHOR]- Published
- 2013
- Full Text
- View/download PDF
8. Protection Against the Extravasation of Anticancer Drugs by Standardization of the Management System.
- Author
-
Watanabe, Hiroyuki, Ikesue, Hiroaki, Yoshida, Minoru, Yamamoto, Naoko, Sakamoto, Setsuko, Koga, Tomoichiro, Sueyasu, Masanori, Egashira, Nobuaki, Inoshima, Ichiro, Nakanishi, Yoichi, and Oishi, Ryozo
- Subjects
ANTINEOPLASTIC agents ,DRUG administration ,CANCER chemotherapy ,DRUG therapy ,VENOUS puncture - Abstract
The extravasation of anticancer drugs is a serious complication. On the basis of data regarding extravasation prevention and treatment obtained primarily by pharmacists, the management system for extravasation of anticancer drugs was standardized at an outpatient chemotherapy center. A kit was prepared so that physicians could promptly and safely perform venipuncture; the kit included a classification list of anticancer drugs. Prior to administration of vesicant or irritant drugs, pharmacists and nurses educated the patients. When anticancer drugs were administered via peripheral vein without using an implanted venous access device, extravasation occurred in 10 out of 7,059 courses (0.14%) during the 2-year study period postintroduction of the present management system. This incidence is remarkably low as compared with those previously reported. The extravasated drugs were epirubicin (n = 3), paclitaxel (n = 3), vinorelbine (n = 1), 5-fluorouracil (n = 1), carboplatin (n = 1), and cyclophosphamide (n = 1). Cold packs were applied around the injection site except in the cases involving vinorelbine, in which warm packs were used. In all cases of extravasation of vesicant drugs, glucocorticoid was injected locally. There were no cases involving continuous pain or skin ulcers. The standardization of the management system for extravasation of anticancer drugs was very effective in decreasing the occurrence, as well as decreasing skin damage if it occurred. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
9. A multicenter phase II study of carboplatin and paclitaxel with a biweekly schedule in patients with advanced non-small-cell lung cancer: Kyushu thoracic oncology group trial.
- Author
-
Ichiki, Masao, Kawasaki, Masayuki, Takayama, Koichi, Ninomiya, Kiyoshi, Kuba, Mutsuo, Iwami, Fumiyuki, Miyazaki, Naoki, Oishi, Kazunori, Takeo, Sadanori, Aizawa, Hisamichi, and Nakanishi, Yoichi
- Subjects
LUNG cancer ,PACLITAXEL ,CANCER chemotherapy ,CLINICAL trials ,HISTOLOGY ,ONCOLOGY - Abstract
Purpose: This multicenter phase II study was conducted to investigate the efficacy and safety of carboplatin in combination with paclitaxel administered according to a biweekly schedule as a first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC). Patients and methods: Eligibility criteria included histologically or cytologically confirmed NSCLC (stage IIIb or IV), no prior treatment, and measurable or evaluable disease. Paclitaxel (140 mg/m
2 ) was administered intravenously on day 1, in combination with carboplatin at an area under the concentration time curve (AUC) of 3, every 2 weeks. Results: Seventy-four patients (45 men) with a median age of 62 years (range 40–74) and a median ECOG performance status of 1 (range 0–2) were enrolled. The response rate was 35.1% [95% confidence interval (CI): 24.4–47.1%], with 26 partial responses. The median survival was 357 days, and the median time to progression was 218 days. Toxicity was generally mild; National Cancer Institute-Common Toxicity Criteria (NCI-CTC) grades 3 and 4 neutropenia was observeded in 50.0% of the patients, and grades 3 and 4 nausea/vomiting in 4.1%. Conclusions: Biweekly carboplatin combined with paclitaxel demonstrated anti-tumor activity in advanced NSCLC, with response and survival rates similar to those of carboplatin combined with paclitaxel administered every 3 weeks but with a more favorable toxicity profile, and the present data indicate that the regimen is suitable for use on an outpatient basis. [ABSTRACT FROM AUTHOR]- Published
- 2006
- Full Text
- View/download PDF
10. Survival Analysis for Patients with ALK Rearrangement‐Positive Non‐Small Cell Lung Cancer and a Poor Performance Status Treated with Alectinib: Updated Results of Lung Oncology Group in Kyushu 1401.
- Author
-
Iwama, Eiji, Goto, Yasushi, Murakami, Haruyasu, Tsumura, Shinsuke, Sakashita, Hiroyuki, Mori, Yoshiaki, Nakagaki, Noriaki, Fujita, Yuka, Seike, Masahiro, Bessho, Akihiro, Ono, Manabu, Nishitsuji, Masaru, Akamatsu, Hiroaki, Morinaga, Ryotaro, Akagi, Takanori, Shimose, Takayuki, Tokunaga, Shoji, Yamamoto, Nobuyuki, Nakanishi, Yoichi, and Sugio, Kenji
- Subjects
ANTINEOPLASTIC agents ,CANCER chemotherapy ,CANCER patients ,CENTRAL nervous system ,CONFIDENCE intervals ,LIFE skills ,LUNG cancer ,METASTASIS ,SURVIVAL analysis (Biometry) ,PROTEIN-tyrosine kinase inhibitors ,ANAPLASTIC lymphoma kinase ,DESCRIPTIVE statistics ,KAPLAN-Meier estimator ,CHEMICAL inhibitors - Abstract
Lessons Learned: Alectinib confers a pronounced survival benefit in patients with ALK rearrangement‐positive non‐small cell lung cancer and a poor performance status.Survival benefit of alectinib for patients with a poor performance status was consistent regardless of the presence of central nervous system metastases. Background: We previously reported a marked objective response rate (ORR) and safety for alectinib treatment in patients with ALK rearrangement‐positive non‐small cell lung cancer (NSCLC) and a poor performance status (PS) in the Lung Oncology Group in Kyushu (LOGiK) 1401 study. It remained unclear, however, whether alectinib might also confer a long‐term survival benefit in such patients. Methods: Eighteen patients with ALK rearrangement‐positive advanced NSCLC and a PS of 2, 3, or 4 (n = 12, 5, and 1, respectively) were enrolled in LOGiK1401 between September 2014 and December 2015 and received alectinib. We have now updated the survival data for the study. Results: The median follow‐up time for all patients was 27.3 months. The median progression‐free survival (PFS) was 16.2 months (95% confidence interval [CI], 7.1–30.8 months), and the median survival time (MST) and the 3‐year overall survival rate were 30.3 months (95% CI, 11.5 months to not reached) and 43.8% (95% CI, 20.8–64.7%), respectively. This survival benefit was similarly manifest in patients with a PS of 2 (MST, 20.5 months) and those with a PS of ≥3 (MST, not reached). PFS did not differ between patients with or without central nervous system (CNS) metastases at baseline (median of 17.5 and 16.2 months, respectively, p =.886). Conclusion: Alectinib showed a pronounced survival benefit for patients with ALK rearrangement‐positive NSCLC and a poor PS regardless of the presence of CNS metastases, a patient population for which chemotherapy is not indicated. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
11. Phase II Study on Biweekly Combination Therapy of Gemcitabine plus Carboplatin for the Treatment of Elderly Patients with Advanced Non‐Small Cell Lung Cancer.
- Author
-
Takayama, Koichi, Ichiki, Masao, Matsumoto, Takemasa, Ebi, Noriyuki, Akamine, Shinji, Tokunaga, Shoji, Yamada, Tadaaki, Uchino, Junji, and Nakanishi, Yoichi
- Subjects
THERAPEUTIC use of antimetabolites ,ADENOCARCINOMA ,ANEMIA ,ANTIMETABOLITES ,CANCER chemotherapy ,COMBINATION drug therapy ,CLINICAL trials ,CONFIDENCE intervals ,DRUG toxicity ,LUNG cancer ,MEDICAL cooperation ,NEUTROPENIA ,PATIENT safety ,RESEARCH ,SURVIVAL ,THROMBOCYTOPENIA ,TREATMENT effectiveness ,DESCRIPTIVE statistics ,CARBOPLATIN ,DRUG administration ,DRUG dosage ,OLD age - Abstract
Lessons Learned: The biweekly GEM plus CBDCA dose and schedule showed satisfactory efficacy with mild toxicities in elderly patients with advanced NSCLC.The biweekly GEM plus CBDCA regimen could be considered an alternative to the 3‐week regimen in NSCLC. Background: The gemcitabine (GEM)‐carboplatin (CBDCA) combination is widely used for non‐small cell lung cancer (NSCLC) and has some efficacy in elderly patients; however, a high incidence of thrombocytopenia is observed, and the optimal dosage and administration schedules are unknown. This multicenter phase II trial evaluated the efficacy and tolerability of GEM‐CBDCA for elderly patients with chemotherapy‐naive NSCLC. Methods: Patients with chemotherapy‐naive performance status 0–1 and with stage IIIB/IV NSCLC were administered chemotherapy biweekly (GEM 1,000 mg/m2 with CBDCA area under the blood concentration‐time curve (AUC) 3 on days 1 and 15 every 4 weeks). The primary endpoint was the objective response rate (ORR), and the secondary endpoints were progression‐free survival (PFS), overall survival (OS), and safety. Results: Forty‐eight patients were enrolled. Median age was 76 years (range, 70–83); 35 patients were men (73%), and 27 patients had adenocarcinoma (56%). The ORR was 29.2% (95% confidence interval [CI], 17.0–44.1). The median PFS, median OS, and 1‐year survival was 5.9 months (95% CI, 4.1–6.6), 13.3 months (95% CI, 8.3–23.5), and 58%, respectively. Grade ≥3 hematological toxicities included neutropenia (29.2%), thrombocytopenia (4.2%), and anemia (20.8%). The incidence of grade ≥3 nonhematological toxicities was <5%. Conclusion: This GEM‐CBDCA combination administered biweekly showed satisfactory efficacy with mild toxicities in elderly patients with advanced NSCLC. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
12. Randomized Phase II Study of Weekly Paclitaxel plus Carboplatin Versus Biweekly Paclitaxel plus Carboplatin for Patients with Previously Untreated Advanced Non‐Small Cell Lung Cancer.
- Author
-
Takayama, Koichi, Ichiki, Masao, Tokunaga, Shoji, Inoue, Koji, Kawasaki, Masayuki, Uchino, Junji, and Nakanishi, Yoichi
- Subjects
PACLITAXEL ,ANTINEOPLASTIC agents ,CANCER chemotherapy ,LUNG cancer ,NEUTROPENIA ,STATISTICAL sampling ,RANDOMIZED controlled trials ,TREATMENT effectiveness ,CARBOPLATIN - Abstract
Copyright of Oncologist is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2019
- Full Text
- View/download PDF
13. Trastuzumab emtansine for patients with non–small cell lung cancer positive for human epidermal growth factor receptor 2 exon-20 insertion mutations.
- Author
-
Iwama, Eiji, Zenke, Yoshitaka, Sugawara, Shunichi, Daga, Haruko, Morise, Masahiro, Yanagitani, Noriko, Sakamoto, Tomohiro, Murakami, Haruyasu, Kishimoto, Junji, Matsumoto, Shingo, Nakanishi, Yoichi, Goto, Koichi, and Okamoto, Isamu
- Subjects
- *
LUNG cancer , *SURVIVAL , *GENETIC mutation , *SEQUENCE analysis , *INTRAVENOUS therapy , *CONFIDENCE intervals , *TRASTUZUMAB , *EPIDERMAL growth factor receptors , *CANCER chemotherapy , *TIME , *HEALTH outcome assessment , *CANCER patients , *SURVIVAL analysis (Biometry) , *DESCRIPTIVE statistics , *POLYMERASE chain reaction , *DRUG toxicity , *PHARMACODYNAMICS - Abstract
Human epidermal growth factor receptor 2 (HER2) mutations are present in ∼3% of patients with non–small cell lung cancer (NSCLC), with exon-20 insertions accounting for ∼90% of such HER2 mutations and having been identified as driver oncogenic alterations. Antibody–cytotoxic drug conjugates including trastuzumab deruxtecan have shown an excellent efficacy for NSCLC with HER2 mutations. We have now performed a phase II study to evaluate the efficacy of ado-trastuzumab emtansine (T-DM1) for NSCLC positive for HER2 exon-20 insertion mutations. Eligible patients with HER2 exon-20 insertion mutations confirmed by next-generation sequencing or multiplex polymerase chain reaction platforms and a history of one or two lines of chemotherapy received T-DM1 (3.6 mg/kg) intravenously every 21 days. The primary end-point of the study was the objective response rate (ORR). Between February 2019 and July 2020, 22 patients were enrolled in the study. A775_G776insYVMA was the most frequent HER2 exon-20 insertion mutation, accounting for 19 (86.4%) of the 22 patients. The ORR was 38.1% (90% confidence interval, 23.0–55.9%), and the disease control rate was 52.4%. The median duration of response was 3.5 months, and the median progression-free survival and median overall survival were 2.8 and 8.1 months, respectively. Toxicity was mild, with the frequency of adverse events of grade ≥3 being low. T-DM1 is a potential treatment option for patients with NSCLC with HER2 exon-20 insertion mutations. Further investigation of biomarkers for T-DM1 is warranted to improve its efficacy for NSCLC with such mutations. JapicCTI-194620 • Ado-trastuzumab emtansine was tested for patients with non-small cell lung cancer. • The objective response rate for T-DM1 in these patients was 38.1%. • Toxicity was mild, with the frequency of adverse events of grade ≥3 being low. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
14. Phase II trial of weekly nab-paclitaxel for previously treated advanced non–small cell lung cancer: Kumamoto thoracic oncology study group (KTOSG) trial 1301.
- Author
-
Sakata, Shinya, Saeki, Sho, Okamoto, Isamu, Otsubo, Kohei, Komiya, Kazutoshi, Morinaga, Ryotaro, Yoneshima, Yasuto, Koga, Yuichiro, Enokizu, Aimi, Kishi, Hiroto, Hirosako, Susumu, Yamaguchi, Emi, Aragane, Naoko, Fujii, Shinji, Harada, Taishi, Iwama, Eiji, Semba, Hiroshi, Nakanishi, Yoichi, and Kohrogi, Hirotsugu
- Subjects
- *
PACLITAXEL , *CANCER treatment , *NON-small-cell lung carcinoma , *CANCER chemotherapy , *MEDICATION safety , *DRUG efficacy , *DISEASE progression , *CLINICAL trials - Abstract
Objectives We performed an open-label, multicenter, single-arm phase II study (UMIN ID 000010532) to prospectively evaluate the efficacy and safety of nab-paclitaxel for previously treated patients with advanced non–small cell lung cancer (NSCLC). Methods Patients with advanced NSCLC who experienced failure of prior platinum-doublet chemotherapy received weekly nab-paclitaxel (100 mg/m 2 ) on days 1, 8, and 15 of a 21-day cycle until disease progression or the development of unacceptable toxicity. The primary end point of the study was objective response rate (ORR). Results Forty-one patients were enrolled between September 2013 and April 2015. The ORR was 31.7% (90% confidence interval, 19.3%–44.1%), which met the primary objective of the study. Median progression-free survival was 4.9 months (95% confidence interval, 2.4–7.4 months) and median overall survival was 13.0 (95% confidence interval, 8.0–18.0 months) months. The median number of treatment cycles was four (range, 1–17) over the entire study period, and the median dose intensity was 89.1 mg/m 2 per week. Hematologic toxicities of grade 3 or 4 included neutropenia (19.5%) and leukopenia (17.1%), with no cases of febrile neutropenia being observed. Individual nonhematologic toxicities of grade 3 or higher occurred with a frequency of <5%. Conclusion Weekly nab-paclitaxel was associated with acceptable toxicity and a favorable ORR in previously treated patients with advanced NSCLC. Our results justify the undertaking of a phase III trial comparing nab-paclitaxel with docetaxel in this patient population. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
15. Phase I clinical trial of a five-peptide cancer vaccine combined with cyclophosphamide in advanced solid tumors.
- Author
-
Murahashi, Mutsunori, Hijikata, Yasuki, Yamada, Kazunari, Tanaka, Yoshihiro, Kishimoto, Junji, Inoue, Hiroyuki, Marumoto, Tomotoshi, Takahashi, Atsushi, Okazaki, Toshihiko, Takeda, Kazuyoshi, Hirakawa, Masakazu, Fujii, Hiroshi, Okano, Shinji, Morita, Masaru, Baba, Eishi, Mizumoto, Kazuhiro, Maehara, Yoshihiko, Tanaka, Masao, Akashi, Koichi, and Nakanishi, Yoichi
- Subjects
- *
CANCER vaccines , *CYCLOPHOSPHAMIDE , *COLON cancer treatment , *CANCER chemotherapy , *IMMUNE response , *CLINICAL trials - Abstract
We designed a phase I trial to investigate the safety, immune responses and clinical benefits of a five-peptide cancer vaccine in combination with chemotherapy. Study subjects were patients positive for HLA-A2402 with locally advanced, metastatic, and/or recurrent gastrointestinal, lung or cervical cancer. Eighteen patients including nine cases of colorectal cancer were treated with escalating doses of cyclophosphamide 4 days before vaccination. Five HLA-A2402-restricted, tumor-associated antigen (TAA) epitope peptides from KOC1, TTK, URLC10, DEPDC1 and MPHOSPH1 were injected weekly for 4 weeks. Treatment was well tolerated without any adverse events above grade 3. Analysis of peripheral blood lymphocytes showed that the number of regulatory T cells dropped from baseline after administration of cyclophosphamide and confirmed that TAA-specific T cell responses were associated significantly with longer overall survival. This phase I clinical trial demonstrated safety and promising immune responses that correlated with vaccine-induced T-cell responses. Therefore, this approach warrants further clinical studies. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
16. A Phase I Study of Chemoradiotherapy With Use of Involved-Field Conformal Radiotherapy and Accelerated Hyperfractionation for Stage III Non-Small Cell Lung Cancer: WJTOG 3305
- Author
-
Tada, Takuhito, Chiba, Yasutaka, Tsujino, Kayoko, Fukuda, Haruyuki, Nishimura, Yasumasa, Kokubo, Masaki, Negoro, Shunichi, Kudoh, Shinzoh, Fukuoka, Masahiro, Nakagawa, Kazuhiko, and Nakanishi, Yoichi
- Subjects
- *
CANCER chemotherapy , *RADIOTHERAPY , *LUNG cancer , *CARBOPLATIN , *PACLITAXEL , *TOXICOLOGY - Abstract
Purpose: A Phase I study to determine a recommended dose of thoracic radiotherapy using accelerated hyperfractionation for unresectable non–small-cell lung cancer was conducted. Methods and Materials: Patients with unresectable Stage III non–small-cell lung cancer were treated intravenously with carboplatin (area under the concentration curve 2) and paclitaxel (40 mg/m2) on Days 1, 8, 15, and 22 with concurrent twice-daily thoracic radiotherapy (1.5 Gy per fraction) beginning on Day 1 followed by two cycles of consolidation chemotherapy using carboplatin (area under the concentration curve 5) and paclitaxel (200 mg/m2). Total doses were 54 Gy in 36 fractions, 60 Gy in 40 fractions, 66 Gy in 44 fractions, and 72 Gy in 48 fractions at Levels 1 to 4. The dose-limiting toxicity, defined as Grade ≥4 esophagitis and neutropenic fever and Grade ≥3 other nonhematologic toxicities, was monitored for 90 days. Results: Of 26 patients enrolled, 22 patients were assessable for response and toxicity. When 4 patients entered Level 4, enrollment was closed to avoid severe late toxicities. Dose-limiting toxicities occurred in 3 patients. They were Grade 3 neuropathy at Level 1 and Level 3 and Grade 3 infection at Level 1. However, the maximum tolerated dose was not reached. The median survival time was 28.6 months for all patients. Conclusions: The maximum tolerated dose was not reached, although the dose of radiation was escalated to 72 Gy in 48 fractions. However, a dose of 66 Gy in 44 fractions was adopted for this study because late toxicity data were insufficient. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.